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Abstract
Purpose: It is vital to understand the associations between the medication event monitoring systems (MEMS) and
self-reported questionnaires (SRQs) because both are often used to measure medication adherence and can
produce different results. In addition, the economic implication of using alternative measures is important as the
cost of electronic monitoring devices is not covered by insurance, while self-reports are the most practical and
cost-effective method in the clinical settings. This meta-analysis examined the correlations of two measurements of
medication adherence: MEMS and SRQs.
Methods: The literature search (1980-2009) used PubMed, OVID MEDLINE, PsycINFO (EBSCO), CINAHL (EBSCO),
OVID HealthStar, EMBASE (Elsevier), and Cochrane Databases. Studies were included if the correlation coefficients
[Pearson (rp) or Spearman (rs)] between adherences measured by both MEMS and SRQs were available or could be
calculated from other statistics in the articles. Data were independently abstracted in duplicate with standardized
protocol and abstraction form including 1) first author’s name; 2) year of publication; 3) disease status of
participants; 4) sample size; 5) mean age (year); 6) duration of trials (month); 7) SRQ names if available; 8)
adherence (%) measured by MEMS; 9) adherence (%) measured by SRQ; 10) correlation coefficient and relative
information, including p-value, 95% confidence interval (CI). A meta-analysis was conducted to pool the correlation
coefficients using random-effect model.
Results: Eleven studies (N = 1,684 patients) met the inclusion criteria. The mean of adherence measured by MEMS
was 74.9% (range 53.4%-92.9%), versus 84.0% by SRQ (range 68.35%-95%). The correlation between adherence
measured by MEMS and SRQs ranged from 0.24 to 0.87. The pooled correlation coefficient for 11 studies was 0.45
(p = 0.001, 95% confidence interval [95% CI]: 0.34-0.56). The subgroup meta-analysis on the seven studies reporting
rp and four studies reporting rs reported the pooled correlation coefficient: 0.46 (p = 0.011, 95% CI: 0.33-0.59) and
0.43 (p = 0.0038, 95% CI: 0.23-0.64), respectively. No differences were found for other subgroup analyses.
Conclusion: Medication adherence measured by MEMS and SRQs tends to be at least moderately correlated,
suggesting that SRQs give a good estimate of medication adherence.
Background
Medical adherence is defined as the extent to which a
patient’s medication taking coincides with medical or
health advice [1]. Despite the proven efficacy of pre-
scription drugs in reducing illness symptoms and pre-
venting or minimizing associated complications,
adherence rates to long-term pharmacotherapy tend to
be approximately 50%, regardless of the illness, regimen
or measurement criteria [2,3]. In addition, the adherence
rate varies with disease conditions, ranging from 15% to
93% as reported in the literature [4]. Failure to adhere
to medication regimens in the United States may cost as
much as $300 billion annually, mediated by ineffective-
ness of treatment and worsening of disease progression
to poor outcomes, disease complications, medication
adverse events, hospitalizations and re-hospitalizations,
emergency department visits, and even death [5].
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a first step towards developing a greater understanding
of the potential for non-adherence and adverse out-
comes. Two methods often used for this purpose are
medication event monitoring systems (MEMS) and self-
reported questionnaires (SRQs) [6]. In spite of the avail-
ability of these measures, they present several technical
challenges in measuring adherence. The MEMS is a
medication vial cap that electronically records the date
and time of bottle opening. It is also known as the
“imperfect gold standard,” [7] due to its recording effec-
tiveness in measurement of patient adherence. However,
it could be time consuming, expensive, resource inten-
sive and may not be suitable for all medications/formu-
lations. Alternatively, self-reported questionnaires
( S R Q s )c o u l db eav e r yc o n v e n i e n tc h o i c ef o rc e r t a i n
study designs. However, SRQs are subject to measure-
ment bias such as social desirability, recall bias, and
response bias; there have been mixed reports about the
accuracy of self-reported adherence [8,9]. Therefore, the
accuracy in measuring medication adherence is uncer-
tain for SRQs. This uncertainty further limits the cred-
ibility and validity of results obtained using SRQs. The
previous literature reviews have focused on some quali-
tative work examining the correlation between SRQs
and other measures such as pharmacy refill records, and
interview [8-10]. Hence, it is vital to understand their
associations relative to electronic measures of adherence
such as MEMS. In addition, the economic implication of
using alternative measures such as SRQs is also impor-
tant as the cost of electronic monitoring devices is not
covered by insurance, and thus these devices are not in
routine use while self-reports are the most useful
method in the clinical setting for practical interventions
on non-adherence.
To advance the knowledge on relationships between
different measurements, this study was the first study
attempting to assess and quantify the correlation
between MEMS and SRQs used for the measurement of
medication adherence. Hence the objective of this study
was to perform a meta-analysis to examine the correla-
tion between MEMS and SRQs.
Methods
Study Selection
The literature search for monitoring devices citations
from 1980-April 2009 was performed using search
terms: patient compliance, medication adherence, treat-
ment compliance, drug monitoring, drug therapy, elec-
tronic, digital, computer, monitor, monitoring, drug,
drugs, pharmaceutical preparations, compliance, and
medications. The search time frame was determined
appropriately because the MEMS technology is available
in 1980 s. We searched the following databases:
P u b M e d ,O V I DM E D L I N E ,P s y c I N F O( E B S C O ) ,
CINAHL (EBSCO), OVID HealthStar, EMBASE (Else-
vier), and Cochrane Databases of Systematic Reviews.
The search was restricted to only human studies. All
results of database search were merged in a single file
for monitoring devices after the duplicates from the
citation list were removed using the Endnote reference
management tool. The initial search was performed in
October of 2008, and updated in April 2009.
Inclusion criteria were (1): an article measuring medi-
cation adherence in clinical trials using both MEMS and
SRQs; (2): the correlation coefficients (Pearson correla-
tion coefficient (rp) or Spearman correlation coefficient
(rs)) between the adherence rates measured by 2 differ-
ent methods were available or could be calculated based
on data published in the study reports.
Figure 1 presents the flow chart documenting how the
research team used to extract the information for study
objectives. From the original citations of 1,857 records,
2 research assistants (YK and JL) independently
reviewed both files and qualitatively determined “most
relevant”“ somewhat relevant”, and “irrelevant” in accor-
dance with the Quality of Reporting of Meta-analyses
(QUOROM) statement, [11] and were re-verified by the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statements, the latter of which
is the most recent standard process for meta-analysis in
2009. Disputes were settled by consensus after reviewing
full-text articles. Where discrepancies between investiga-
tors occurred for inclusion or exclusion, the principal
investigator (LS) was involved to conduct additional eva-
luation of the study and resolve the dispute.
Data Abstraction
Data were independently abstracted in duplicate with
the standardized protocol and abstraction form. The
study characteristics recorded were as follows: 1) first
author’s name; 2) year of publication; 3) disease status
of participants; 4) sample size; 5) mean age (year); 6)
duration of trials (month); 7) SRQ names if available or
anonymous if a specific name is unavailable in the arti-
cle; 8) adherence (%) measured by MEMS; 9) adherence
(%) by SRQ; 10) correlation coefficient and relative
information, including p-value, 95% confidence interval
(CI). If data concerning the outcome were missing from
an article, the investigators attempted to contact the pri-
mary author in order to obtain this missing data.
Statistical Analysis
This meta-analysis was conducted according to the
QUOROM guidelines [11] and PRISMA statements for
the conduct and reporting of meta-analyses. Standard
methods were used to calculate the pooled variance
[12], which were calculated using CIs, p-values,
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adherence measurements. When a paper reported
p < 0.05, p < 0.01, p < 0.001 or NS, we computed stan-
dard error of correlation coefficient with p values of
0.025, 0.005, 0.0005, 0.50, respectively, which likely
gained a highly conservative estimate of the correlation
coefficient [13]. Both fixed-effects and DerSimonian and
Laird’s random effects models were used to calculate
the pooled correlation coefficient [14]. The 2 models
approximate each other in the absence of heterogeneity.
Heterogeneity was assessed using the chi-square test sta-
tistic. The random effect model was selected in this
meta-analysis to synthesize correlation coefficient due to
heterogeneity among the reviewed studies. We pre-
sented data for random-effects models throughout
because of the different demographic characteristics,
measurement methods, and study durations that were
involved in the original trials. Publication bias was
examined using the Begg-adjusted rank correlation test
based on Kendall’s score and Egger regression asym-
metric test [15]. Two subgroup post-hoc meta-analyses
(studies reporting Pearson correlation coefficient and
Spearman rank correlation coefficient; HIV studies vs.
non-HIV studies) were also conducted to investigate
potential differences, to address these naturally occur-
ring groups in the population of studies. All analyses
were conducted in STATA version 10.1 (Stata Corp.,
College Station, TX). The significance was set at 2-tailed
p-values of 0.05.
Results
Basic characteristics of studies
Figure 1 presents the flow chart to describe the process
of selecting the studies for meta-analysis. Out of 1,857
Figure 1 Flow Chart of Articles Identified and Evaluated during the Study Selection Process.
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as concurrent monitoring methods (n = 138). After
restricting the articles with correlation between the 2
methods, we only found 11 articles (7 with rp and 4
with rs). Table 1 summarizes the basic characteristics of
studies investigating the correlation between adherence
measured by MEMS and SRQs. Across 11 articles finally
included in the meta-analysis [16-26], 7 (63.6%) studies’
p a r t i c i p a n t sw e r eH I Vp a t i e n t s .T h es a m p l es i z eo f
included studies ranged from 26 to 568, 153 on average.
The mean age was 42.9 years, with a range of 23 to
62 years. The trial period averaged 4.6 months (range
0.5 to 12 months). The mean of adherence measured by
MEMS was 74.9% (range 53.4% to 92.9%), compared to
84.0% by the self-report questionnaires (range 68.35% to
95.0%).
The correlation between adherence measured by
MEMS and self-report questionnaires ranged from 0.24
to 0.87 for the 11 articles. We found 7 (63.6%) articles
reporting Pearson correlation coefficient (rp)
[17,19-22,24,26] and 4 (36.4%) using Spearman rank
correlation coefficient (rs) [16,18,23,25].
Meta-analysis Results
Figure 2 presents the combined correlation coefficient for
11 studies was 0.45 (p = 0.001, 95% CI: 0.34-0.56). The
subgroup meta-analysis on the studies reporting Pearson
correlation coefficient and Spearman rank correlation
coefficient showed the pooled correlation coefficient 0.46
(p = 0.011, 95% CI: 0.33-0.59) and 0.43 (p = 0.038, 95%
CI: 0.23-0.64), respectively. Additionally, another subgroup
meta-analysis on HIV patients in the 7 reviewed studies
found the pooled correlation coefficient 0.51 (p = 0.014,
95% CI: 0.37-0.64) and non-HIV studies found the pooled
correlation coefficient 0.45 (p = 0.001, 95% CI: 0.34-0.56).
The test for heterogeneity among the reviewed studies
showed statistically significance in both categories (both
p-values < 0.05) and the overall analysis (p = 0.001).
Given the heterogeneity statistics presented, we only
reported the results of the random-effects models as
appropriate models for combining the individual studies.
As to publication bias, the Egger test showed the
intercept in the regression of the standardized effect
estimates against their precision was -0.75 (p = 0.40,
95% CI: -2.69-1.19) while the Begg test showed a mar-
ginally statistical significance (p = 0.052).
Discussion
This is the first study to our best knowledge to quantify
the correlation between the MEMS and SRQs for mea-
suring adherence. We only found a small number of
studies which have met the inclusion criteria for meta-
analysis. We have found at least moderate correlation
using a meta-regression model to pool the correlation
coefficients from a total of 11 studies. These findings
are consistent with previous studies on the moderate-to-
high correlation of self-report with other measures of
medication adherence [8-10,27].
The systematic measurement of medication adherence
is not routinely performed in outpatient settings due to
a lack of reliable, convenient, economical methods for
measuring adherence. The key advantages and limita-
tions of various methods have been well summarized in
the literature [28]. The selection of medication adher-
ence measures should tailor to the goals and resources
available for the intended use and attributes of each
Table 1 Basic characteristics of studies investigating the correlation between adherence rates measured by MEMS and
SRQs
Author Year Disease Sample
Size
Age
(years)
Duration
(months)
Self-Report
Questionnaires
MEMS-
Monitored
Adherence
(%)
Self-Report
Adherence
(%)
Correlation
(rp or rs)
Arnsten J. 2001 HIV 133 43 6 Anonymous 53.4 78.1 0.46
Hugen P.W. 2002 HIV 26 39.9 0.5 VAS 91.1 86 0.73
Walsh J.C 2002 HIV 78 - 6 MASRI 92.9 93.3 0.63
Hamilton G.A. 2003 Hypertension 107 58 - MOS, Morisky, VAS 58.38 81.05 0.26
Oyugi J.H. 2004 HIV 36 35 3 AACTG 90.9 93.5 0.87
Fletcher C.V. 2005 HIV 258 40 12 AACTG 64 82 0.24
Halkitis P. 2005 HIV 300 42 - Anonymous 90 95 0.32
Jasti S. 2006 Iron deficiency 51 23 - Anonymous 68.1 76.5 0.35
Byerly M.J. 2008 Schizophrenia 61 44.3 6 BARS 66.81 68.35 0.59
Lu M. 2008 HIV 568 42 1 Anonymous 69.8 78.8 0.55
Zeller A. 2008 Hypertension Diabetes
Dysdipidemia
66 62 2.5 ASRQ 79 91.3 0.29
BARS: Brief adherence rating scale; AACTG: Adult AIDS clinical trials group adherence instrument; MEMS: Medication event monitoring systems; MOS: Medical
outcomes study; Morisky: Morisky adherence rating scale; VAS: Visual analog scale; MASRI: Medication adherence self-report inventory; ASRQ: Adherence self-
report questionnaire; Anonymous: A questionnaire without a specific name in a reviewed article.
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collect different sets of information using different
approaches and perspectives. When used together, the 2
methods complement each other giving confidence to
the results, and tend to support the same conclusion.
The meta-analysis summarizes and advances the field of
adherence research through a side-to-side examination
on two types of measurements within a study. Our find-
ing of the pooled correlation coefficient of approximate
0.45 supports the need of multiple measures in the
future adherence research because neither the MEMs
nor SRQs can replace each other.
Furthermore, we have found that most of SRQs used
in the meta-analysis were generic measures for medica-
tion adherence. For example, among these question-
naires, the Adult AIDS Clinical Trials Group (AACTG)
instruments were most frequently used to evaluate clini-
cal interventions, including the efficacy of drugs and
drug combinations for treating HIV infection and HIV-
associated illnesses [29]. This is a standard self-adminis-
tered questionnaire based on previous research on
adherence. The questionnaire has been in use for over
10 years and patients demonstrated high satisfaction
with its length [30,31]. Similarly, the Morisky Scale is
widely used to measure medication adherence in various
populations (e.g., asthma [32], cancer [33], osteoporosis
[34]). It was originally developed to measure hyperten-
sion and demonstrated high concurrent and predictive
validity with regard to blood pressure control. The 4
items scale and its modified versions: 8- and 5-item
scales are relatively simple to use and could be utilized
to measure adherence [35,36]. The Medication Adher-
ence Self-Report Inventory (MASRI) is a 12-item ques-
tionnaire originally developed for HIV [17] and systemic
lupus [37]. However, in contrast to those well-known
SRQs, most of the reviewed anonymous questionnaires
(4 studies) also found low correlation with MEMS.
Therefore, the validity of these anonymous question-
naires was not satisfactory for further development.
T h e s ef i n d i n g sm u s tb ei n t e r p r e t e di nt h ec o n t e x to f
the methodological weaknesses of this study, particularly
for the heterogeneity of SRQs in the limited number of
included studies. First, some studies have different defini-
tions of adherence, in addition to the variations in study
populations, disease states, and study duration. For exam-
ple, most studies were in HIV patients where adherence
is very high. In contrast, for 2 studies that examined non-
symptomatic disease such as hypertension, correlation
Figure 2 Correlation coefficients between adherences measures by MEMS and self reported questionnaires and corresponding 95%
confidence intervals by study and pooled.
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published to assess adherence-response relationships,
particularly when adherence is subject to measurement
error [38,39]. Secondly, the information on some SRQs is
limited in the study reports, even without a specific name
for the SRQs in 4 articles. Thirdly, 2 simplistic correla-
tion measures, Pearson correlation coefficients and
Spearman correlation coefficients, have been used in the
meta-analysis. With the focus on the correlation coeffi-
cients, we had an implicit assumption that the association
between electronically measured and self-reported adher-
ence rates is linear. Obviously, a non-linear association is
possible in the true association for research in the future.
Additionally, we have tested the heterogeneity among the
studies with a finding of significance. To address the
issue of heterogeneity, which is quite common in meta-
analysis, we have adopted random-effect models in the
meta-analysis due to heterogeneity. We have also done
two subgroup analyses to explore some possible influ-
ences of heterogeneity. The results of subgroup analyses
did not find substantial differences because the results of
95% CI were overlapping for the pooled estimates. Lastly,
measuring the level of agreement (not just association)
between the MEMS and questionnaire data should be
considered in future studies. The Pearson product-
moment correlation is a measure of association, not
agreement. Perhaps we may also extract an indicator
such as the intraclass correlation.
Other limitations should also be mentioned. Although
the authors have made attempts to identify all available
studies for meta-analysis, there could have been studies
that were missed. For example, a recent study was
excluded due to the use of different measure of correla-
tion coefficient Kendall tau [27]. Inclusion of other self-
reported methods such as diary, claims data, and clinical
opinion could potentially be explored in the future.
Lastly, the generalizability of the study results is limited
as majority of the studies identified as measuring adher-
ence were in HIV and few were in hypertension, schizo-
phrenia and diabetes.
Conclusion
Based on the pooled estimate using meta-analysis, at
least moderate correlation was found between adher-
ences measured by MEMS and SRQs. Therefore, SRQs
provide a good estimate of patient medication adher-
ence. If possible, MEMS and SRQs should be used com-
plementarily to get accurate measure for patient
adherence.
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